6-Thioguanine and Its Analogs Promote Apoptosis of Castration-Resistant Prostate Cancer Cells in a BRCA2-Dependent Manner (scientific article published on 05 July 2019)

BRCA2 is ubiquitinated in vivo and interacts with USP11, a deubiquitinating enzyme that exhibits prosurvival function in the cellular response to DNA damage

Q24301487

6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance

Q24599364

Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes

Q24645701

Prostate cancer stem cells: the role of androgen and estrogen receptors

Q26778415

The expanding role of yeast in cancer research and diagnosis: insights into the function of the oncosuppressors p53 and BRCA1/2

Q26851138

Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer.

Q52838313

EMT, cell plasticity and metastasis.

Q53666394

Aberrations of DNA Repair Pathways in Prostate Cancer: Future Implications for Clinical Practice?

Q57106332

Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic

Q57903135

Prostate Cancer Progression and Survival in BRCA2 Mutation Carriers

Q58143504

A drug-repositioning screen for primary pancreatic ductal adenocarcinoma cells identifies 6-thioguanine as an effective therapeutic agent for TPMT-low cancer cells

Q58694415

Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer

Q62746983

ZFHX3 is indispensable for ERβ to inhibit cell proliferation via MYC downregulation in prostate cancer cells

Q64120368

Effect of the expression of BRCA2 on spontaneous homologous recombination and DNA damage-induced nuclear foci in Saccharomyces cerevisiae

Q64386389

Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation

Q73923040

Tackling Cancer with Yeast-Based Technologies

Q90743439

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Q27860519

Anoikis resistance: an essential prerequisite for tumor metastasis

Q28397372

6-thioguanine: a drug with unrealized potential for cancer therapy

Q33829767

Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study

Q33927384

Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis.

Q34168304

Thioguanine, Mercaptopurine: Their Analogs and Nucleosides as Antimetabolites

Q34267931

In vivo amplification of the androgen receptor gene and progression of human prostate cancer

Q34314274

Cancer risks in BRCA2 mutation carriers

Q34504452

DU-145 and PC-3 human prostate cancer cell lines express androgen receptor: implications for the androgen receptor functions and regulation

Q34507943

BRCA2: a universal recombinase regulator.

Q34655484

Skp2 overexpression is associated with loss of BRCA2 protein in human prostate cancer

Q34838226

Secondary mutations of BRCA1/2 and drug resistance

Q34983549

BRCA1 and BRCA2 protect against oxidative DNA damage converted into double-strand breaks during DNA replication

Q35641332

The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens

Q35996429

Germline BRCA mutations denote a clinicopathologic subset of prostate cancer

Q37019841

The essential role of methylthioadenosine phosphorylase in prostate cancer.

Q37046624

Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer

Q37179254

Drug resistance caused by reversion mutation

Q37346915

Mitochondrial DNA depletion sensitizes cancer cells to PARP inhibitors by translational and post-translational repression of BRCA2.

Q37614527

Interconnections between apoptotic and autophagic pathways during thiopurine-induced toxicity in cancer cells: the role of reactive oxygen species

Q37688995

Targeting tumors that lack methylthioadenosine phosphorylase (MTAP) activity: current strategies

Q37837359

Steps in prostate cancer progression that lead to bone metastasis

Q37848782

Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage.

Q38467346

Role of taxanes in advanced prostate cancer.

Q38726366

Silencing of BRCA2 decreases anoikis and its heterologous expression sensitizes yeast cells to acetic acid-induced programmed cell death

Q38987920

Androgen receptor expression in prostate cancer cells is suppressed by activation of epidermal growth factor receptor and ErbB2.

Q39843676

Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype

Q40002565

The impact of a BRCA2 mutation on mortality from screen-detected prostate cancer

Q40213120

Gene deletion chemoselectivity: codeletion of the genes for p16(INK4), methylthioadenosine phosphorylase, and the alpha- and beta-interferons in human pancreatic cell carcinoma lines and its implications for chemotherapy

Q41223446

Paclitaxel-induced microtubule stabilization causes mitotic block and apoptotic-like cell death in a paclitaxel-sensitive strain of Saccharomyces cerevisiae

Q41421868

Estrogen receptor signaling in prostate cancer: Implications for carcinogenesis and tumor progression.

Q47671734

6-Thioguanine is a noncompetitive and slow binding inhibitor of human deubiquitinating protease USP2.

Q49958810

P275

Creative Commons Attribution 4.0 International

copyrighted